BACKGROUND: The use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the risk of esophageal adenocarcinoma; however, it is unknown where these agents may act in the proposed pathway from normal mucosa to Barrett's esophagus to esophageal adenocarcinoma. AIM: The aim of the study was to evaluate the association between aspirin and NSAID use and Barrett's esophagus in a case-control study within a large community-based population. METHODS: We conducted a case-control study of aspirin/NSAID use and Barrett's esophagus within the Kaiser Permanente Northern California population. Cases had a new diagnosis of Barrett's esophagus between October 2002 and September 2005; controls were members without a diagnosis of Barrett's esophagus. RESULTS: Persons with Barrett's esophagus were less likely to use aspirin than population controls [odds ratio (OR) 0.59, 95 % confidence interval (CI) 0.39-0.87]; a stronger association was found among cases and controls with reflux symptoms (OR 0.49, 95 % CI 0.32-0.75; p value interaction = 0.004). Similar associations were found with the use of either aspirin and/or non-aspirin NSAIDs (OR 0.53, 95 % CI 0.35-0.81), although NSAID use alone was not significantly associated with Barrett's esophagus (OR 0.74, 95 % CI 0.47-1.16). The strength of the association was highest among persons with at least moderate-to-high total medication intake. CONCLUSIONS: Regular use of aspirin or NSAIDs was associated with a decreased risk of Barrett's esophagus, particularly among persons with gastroesophageal reflux disease symptoms. These findings have implications for chemoprevention, as some of the previously described protective association between aspirin/NSAIDs and esophageal adenocarcinoma may be explained by events that occur prior to the development of Barrett's esophagus.
BACKGROUND: The use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the risk of esophageal adenocarcinoma; however, it is unknown where these agents may act in the proposed pathway from normal mucosa to Barrett's esophagus to esophageal adenocarcinoma. AIM: The aim of the study was to evaluate the association between aspirin and NSAID use and Barrett's esophagus in a case-control study within a large community-based population. METHODS: We conducted a case-control study of aspirin/NSAID use and Barrett's esophagus within the Kaiser Permanente Northern California population. Cases had a new diagnosis of Barrett's esophagus between October 2002 and September 2005; controls were members without a diagnosis of Barrett's esophagus. RESULTS:Persons with Barrett's esophagus were less likely to use aspirin than population controls [odds ratio (OR) 0.59, 95 % confidence interval (CI) 0.39-0.87]; a stronger association was found among cases and controls with reflux symptoms (OR 0.49, 95 % CI 0.32-0.75; p value interaction = 0.004). Similar associations were found with the use of either aspirin and/or non-aspirin NSAIDs (OR 0.53, 95 % CI 0.35-0.81), although NSAID use alone was not significantly associated with Barrett's esophagus (OR 0.74, 95 % CI 0.47-1.16). The strength of the association was highest among persons with at least moderate-to-high total medication intake. CONCLUSIONS: Regular use of aspirin or NSAIDs was associated with a decreased risk of Barrett's esophagus, particularly among persons with gastroesophageal reflux disease symptoms. These findings have implications for chemoprevention, as some of the previously described protective association between aspirin/NSAIDs and esophageal adenocarcinoma may be explained by events that occur prior to the development of Barrett's esophagus.
Authors: Zehra B Omer; Ashwin N Ananthakrishnan; Kevin J Nattinger; Elisabeth B Cole; Jesse J Lin; Chung Yin Kong; Chin Hur Journal: Clin Gastroenterol Hepatol Date: 2012-03-15 Impact factor: 11.382
Authors: D C Farrow; T L Vaughan; P D Hansten; J L Stanford; H A Risch; M D Gammon; W H Chow; R Dubrow; H Ahsan; S T Mayne; J B Schoenberg; A B West; H Rotterdam; J F Fraumeni; W J Blot Journal: Cancer Epidemiol Biomarkers Prev Date: 1998-02 Impact factor: 4.254
Authors: Alberto Pilotto; Marilisa Franceschi; Gioacchino Leandro; Carlo Scarcelli; Luigi P D'Ambrosio; Davide Seripa; Francesco Perri; Valeria Niro; Francesco Paris; Angelo Andriulli; Francesco Di Mario Journal: J Am Geriatr Soc Date: 2006-10 Impact factor: 5.562
Authors: Elizabeth H Ruder; Adeyinka O Laiyemo; Barry I Graubard; Albert R Hollenbeck; Arthur Schatzkin; Amanda J Cross Journal: Am J Gastroenterol Date: 2011-03-15 Impact factor: 10.864
Authors: Douglas A Corley; Ai Kubo; Theodore R Levin; Gladys Block; Laurel Habel; Wei Zhao; Pat Leighton; Charles Quesenberry; Greg J Rumore; Patricia A Buffler Journal: Gastroenterology Date: 2007-04-25 Impact factor: 22.682
Authors: Xiaofang Huo; Xi Zhang; Chunhua Yu; Edaire Cheng; Qiuyang Zhang; Kerry B Dunbar; Thai H Pham; John P Lynch; David H Wang; Robert S Bresalier; Stuart J Spechler; Rhonda F Souza Journal: Gut Date: 2017-04-25 Impact factor: 23.059
Authors: Oksana Zayachkivska; Nazar Bula; Dzvinka Khyrivska; Elena Gavrilyuk; John L Wallace Journal: Inflammopharmacology Date: 2015-02-25 Impact factor: 4.473
Authors: Aaron P Thrift; Lesley A Anderson; Liam J Murray; Michael B Cook; Nicholas J Shaheen; Joel H Rubenstein; Hashem B El-Serag; Thomas L Vaughan; Jennifer L Schneider; David C Whiteman; Douglas A Corley Journal: Am J Gastroenterol Date: 2016-08-30 Impact factor: 10.864
Authors: Katarzyna Magierowska; Dominik Bakalarz; Dagmara Wójcik; Edyta Korbut; Aleksandra Danielak; Urszula Głowacka; Robert Pajdo; Grzegorz Buszewicz; Grzegorz Ginter; Marcin Surmiak; Sławomir Kwiecień; Anna Chmura; Marcin Magierowski; Tomasz Brzozowski Journal: Cells Date: 2020-05-12 Impact factor: 6.600